Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Limited is accelerating its global expansion plans for Remplir™, following strong early sales in Australia, New Zealand, and Singapore. With a regulatory application submitted for the U.S. market and plans in place to enter Canada, Thailand, the UK, the EU, and Brazil in 2025, the company aims to capture a 20% share of an estimated US$3.2 billion market. The company’s robust financial position, with $33 million in cash, supports its strategy to broaden its commercial footprint and enhance revenue opportunities.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing collagen-based medical devices. Their primary product, Remplir™, is a collagen wrap used in nerve repair surgeries, aimed at improving outcomes in the repair and regeneration of damaged nerves. It is currently approved for sale in Australia, New Zealand, and Singapore, and is distributed by Device Technologies.
YTD Price Performance: -5.54%
Average Trading Volume: 1,555,446
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$307.1M
See more data about OCC stock on TipRanks’ Stock Analysis page.
